## DisclosureEquityIncentivePlansTables

**Year Ended**

|  | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
| --- | --- | --- | --- |
| **  Summary of Stock Option and RSU Activity** | The following table summarizes our stock option and RSU activity:

                                                                   Weighted-    
Weighted-              
                                                    Weighted-      Average      
Average                
                                                    Average        Remaining    
Grant                  
                                                    Exercise       Contractual  
Date Fair              
                                                    Price          Life (Years) 
Value                  
  Balance, December 31, 2017        10,881,025      $105.56                     
4,689,310      $              265.43  
  Granted                           22,535,566      $346.56                     
3,043,155      $              316.46  
  Exercised or released             (1,386,509      $120.40                     
(1,724,395      $              258.51  
  Cancelled                           (822,228      $315.48                     
(1,349,156      $              278.10  
  Balance, December 31, 2018        31,207,854      $273.40        7.6          
4,658,914      $              294.63  
  Vested and expected to vest,      15,312,577      $206.44        6.4          
4,656,864      $              294.62  
  Exercisable and vested,            7,877,652      $83.45         3.9
 |  |  |
| **  Schedule of Fair Value of Stock Option Award and ESPP on Grant Date** | We use the fair value method in recognizing stock-based compensation expense. 
Under the fair value method, we estimate the fair value of each stock option 
award with service or service and performance conditions and the ESPP on the 
grant date generally using the Black-Scholes option pricing model and the 
weighted-average assumptions in the following table:

                                        Year Ended December 31,                 
                                        2018                                    
2017                  2016             
 ───────────────────────────────────────────────────────────────────────────────
─────────────────────────────────────────
  Risk-free interest rate:                                                      
  Stock options                                                         2.5     
1.8                  1.5  
  ESPP                                                                  2.0     
1.1                  0.6  
  Expected term (in years):                                                     
  Stock options                                                         4.7     
5.1                  6.2  
  ESPP                                                                  0.5     
0.5                  0.5  
  Expected volatility:                                                          
  Stock options                                                          42     
42                   47  
  ESPP                                                                   43     
35                   41  
  Dividend yield:                                                               
  Stock options                                                         0.0     
0.0                  0.0  
  ESPP                                                                  0.0     
0.0                  0.0  
  Grant date fair value per share:                                              
  Stock options                         $                            121.92     
$         122.25      $         98.70  
  ESPP                                  $                             84.37     
$          75.05      $         51.31
 |  |  |
| **  Summary of Operational Milestone Based on Revenue or Adjusted EBITDA** | Total Annualized Revenue      Annualized Adjusted EBITDA  
             (in billions)                                  
                                             (in billions)  
 ────────────────────────────────────────────────────────────
                     $20.0                            $1.5  
                     $35.0                            $3.0  
                     $55.0                            $4.5  
                     $75.0                            $6.0  
                    $100.0                            $8.0  
                    $125.0                           $10.0  
                    $150.0                           $12.0  
                   $ 175.0                           $14.0
 |  |  |
| **  Summary of Stock-Based Compensation Expense** | The following table summarizes our stock-based compensation expense by line item
in the consolidated statements of operations (in thousands):

                                           Year Ended December 31,              
                                           2018                                 
2017                   2016               
 ───────────────────────────────────────────────────────────────────────────────
────────────────────────────────────────────────
  Cost of revenues                         $                             85,742 
$          43,845      $          30,400  
  Research and development                                              261,079 
217,616                154,632  
  Selling, general and administrative                                   398,326 
205,299                149,193  
  Restructuring and other                                                 3,877 
—                      —  
  Total                                    $                            749,024 
$         466,760      $         334,225
 |  |  |